Targeting the programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) pathways using the combination immune checkpoint inhibitors (ICI) nivolumab and ipilimumab is an approved frontline therapy for patients with metastatic clear-cell renal cell carcinoma (mc...
Safety data are given in Table2. Overall, 50% of the patients who received nivolumab–ipilimumab and 52% of the patients who received nivolumab–ipilimumab plus CBM588 had a grade 3 or 4 adverse event attributable to the treatment. Notable grade 3 or 4 toxicities observed in this series incl...
Methods: Eligible patients for this Phase 2 study are previously untreated patients ≥ 18 years of age with unresectable or metastatic soft tissue sarcoma, with measurable disease by RECIST v1.1. Immune checkpoint inhibitors Ipilimumab (I) and Nivolumab (N) were given with Trabectedin (T), a ...
Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI). Ernstoff describes the 2:1 randomization of this phase II study. He mentions that...
It is possible that because the PD-1 and PD-L1 checkpoint acts later in the T cell response, which results in a more restricted T cell reactivity toward tumor cells, nivolumab is well-tolerated in clinical practice [20]. In addition, it should be noted that most of the ipilimumab studies...
We examined expression of three molecular effectors of the PD-1 axis in 234 patients with musculoskeletal tumors, including osteosarcoma, chondrosarcoma, synovial sarcoma, and giant cell tumor. Survival analyses and potential mechanisms were investigated in osteosarcoma per the Gene Expression Omnibus (GEO...
Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942-948. doi:10.1038/s41586-022-04508-4 Related Videos Dr D'Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes ...
1. Incidence of adverse events;From start of treatment through 28 days post-treatment (estimated to be 6 months);-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting. 2. Durat...
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant Nivo+
IpilimumabNivolumabPD-1 blockadePD-L1 statusCheckpoint inhibitor therapy has been shown to improve outcomes in multiple solid malignancies; however, data are limited in soft tissue sarcoma. We present two cases of patients with advanced soft tissue sarcoma of different subtypes (dedifferentiated ...